Finance

Lists
MRK:ETR
Merck KGaA
€137,85
+1,58%
(+2,15) 1D
9 Okt., 17:39:06 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for MRK...
Open
€136,95
High
€138,75
Low
€136,90
Mkt. cap
17,70 mjd
Avg. vol.
293,97 k
Volume
197,78 k
Dividend
1,60%
Quarterly dividend
€0,55
Ex-dividend date
27 Apr. 2026
P/E ratio
25,28
52-wk high
€148,80
52-wk low
€100,70
EPS
€5,45
Shares outstanding
129,24 m
No. of employees
62 k
Open
€136,95
High
€138,75
Low
€136,90
Mkt. cap
17,70 mjd
Avg. vol.
293,97 k
Volume
197,78 k
Dividend
1,60%
Quarterly dividend
€0,55
Ex-dividend date
27 Apr. 2026
P/E ratio
25,28
52-wk high
€148,80
52-wk low
€100,70
EPS
€5,45
Shares outstanding
129,24 m
No. of employees
62 k
News stories
From web sources and news partners
Profile
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally. Merck operates in Europe, Africa, Asia, Oceania and the Americas. It has major research and development centres in Darmstadt, Boston, Shizuoka and Beijing, as well as other Research and Development units in Taiwan, France, Israel, South Korea, India, and the UK. Merck pioneered the commercial manufacture of morphine in the 19th century and for a time held a virtual monopoly on cocaine. Merck was privately owned until going public on the Frankfurt Stock Exchange in 1995 and is listed on the DAX index of Germany's top companies. The Merck family still controls a majority of 70.3% of the company's shares. Wikipedia
About Merck KGaA
CEO-
Employees62,1 k
Founded1668
Headquarters-
SectorPharmaceutical industry
Last report
06 Aug. 2026
Fiscal period
Q2 2026
€2,16 / €2,05
+5,32%beat
Revenue / Est. (EUR)
5,43 mjd / 5,30 mjd
+2,44%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
5,32 mjd
5,25 mjd
5,13 mjd
5,43 mjd
Cost of goods sold
2,10 mjd
2,20 mjd
2,07 mjd
2,27 mjd
Cost of revenue
2,10 mjd
2,20 mjd
2,07 mjd
2,27 mjd
Research and development expenses
660,00 m
634,00 m
657,70 m
684,00 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,46 mjd
1,54 mjd
1,52 mjd
1,56 mjd
Operating expense
1,99 mjd
2,12 mjd
2,13 mjd
2,41 mjd
Total operating expenses
4,10 mjd
4,32 mjd
4,20 mjd
4,68 mjd
Operating income
1,22 mjd
926,00 m
935,40 m
753,00 m
Other non operating income
1,00 m
4,00 m
-100,00 k
-1,00 m
EBT including unusual items
1,12 mjd
401,00 m
868,70 m
640,00 m
EBT excluding unusual items
1,12 mjd
1,10 mjd
867,50 m
640,00 m
Income tax expense
225,00 m
77,00 m
200,00 m
146,00 m
Effective tax rate
20,04%
19,20%
23,02%
22,81%
Other operating expenses
-128,00 m
-50,00 m
-45,40 m
164,00 m
Net income
902,00 m
319,00 m
659,40 m
490,00 m
Net profit margin
16,96%
6,08%
12,84%
9,02%
Earnings per share
-
-
-
2,16
Interest and investment income
27,00 m
21,00 m
21,20 m
25,00 m
Interest expense
-126,00 m
-43,00 m
-80,60 m
-137,00 m
Net interest expenses
-99,00 m
-22,00 m
-59,40 m
-112,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
1,68 mjd
1,31 mjd
1,42 mjd
1,25 mjd
Gain or loss from assets sale
-174,00 m
6,00 m
-41,90 m
1,00 m
AI content may include mistakes. Learn more
Google-programme